Evidence map›Paper›PMID 39014366›Full record

ReviewMolecular cancer2024

Clinical application of liquid biopsy in colorectal cancer: detection, prediction, and treatment monitoring.

Xiang-Yuan Tao, Qian-Qian Li, Yong Zeng

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06778382 (Deferred Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After NED in Colorectal Cancer： A Phase II, Single-Arm Clinical Trail.), which is not on this map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06778382 phase2recruitingnot on this map

Deferred Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After NED in Colorectal Cancer： A Phase II, Single-Arm Clinical Trail.

TypeinterventionalSponsorShandong Cancer Hospital and InstituteRan2024 to 2026Enrolled22ConditionsColorectal Neoplasms MalignantArmsOligometastasis Treatment
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Observational
  19. Exploring the molecular function of LYPD3 from pan-cancer to lung cancer: based on bioinformatics and cellular experiments.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiang-Yuan Tao *Translational Medicine Center, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Qian-Qian Li *Translational Medicine Center, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Yong ZengTranslational Medicine Center, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. valzeng@sina.cn.

Funding

Clinical Research Center For Gastrointestinal Cancer In Hunan Province No.2021SK4016Hunan Cancer Hospital Climb Plan No.20210401-1001; No. 2020IIT002Key Project of Changsha Science and Technology Bureau No. kq1706046Key Research and Development Project of Hunan Science and Technology Department No. 2018SK2126National Natural Science Foundation No.81201730the Natural Science Foundation of Hunan Province No. 12JJ5073
6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most prevalent malignancies affecting the gastrointestinal tract and is ranked third among cancers with the highest incidence and second-highest mortality rate worldwide. CRC exhibits a slow progression providing a wide treatment window. The currently employed CRC screening methods have shown great potential to prevent CRC and reduce CRC-related morbidity and mortality. The diagnosis of CRC is achieved by colonoscopy and tissue biopsy, with studies showing that liquid biopsy is more effective in detecting and diagnosing early CRC patients. Increasing number of studies have shown that the tumor components shed into circulating blood can be detected in liquid form, and can be applied in the clinical management of CRC. Analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or tumor-associated platelets (TEPs) in the blood can be used for early screening and diagnosis of CRC, aid tumor staging, treatment response monitoring, and prediction of CRC recurrence and metastasis in a minimally invasive manner. This chapter provides an updated review of CTCs, ctDNA, and TEPs as novel biomarkers for CRC, highlighting their strengths and limitations.

Indexed as

Biomarkers, TumorCirculating Tumor DNAColorectal NeoplasmsNeoplastic Cells, CirculatingAnimalsDisease ManagementEarly Detection of CancerHumansLiquid BiopsyPrognosisBiomarkers, TumorCirculating Tumor DNACirculating tumor cellsCirculating tumor DNAClinical applicationColorectal cancerLiquid biopsyTumor-associated platelets

Identifiers

PMID39014366
PMCPMC11250976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.